CTI BIOPHARMA CORP. (NASDAQ:CTIC) Files An 8-K Results of Operations and Financial Condition
Item 9.01Results of Operations and Financial Condition.

The information provided to this Item 9.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any filing or other document filed by the Company to the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document. The information provided to this Item 9.01 shall instead be deemed “furnished.”

On March 7, 2018, CTI BioPharma Corp. issued a press release announcing its financial results for the quarter and year ended December 31, 2017 and certain other information. The full text of the press release is set forth in Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

CTI BIOPHARMA CORP Exhibit
EX-99.1 2 earningsreleaseye2017final.htm EXHIBIT 99.1 Exhibit CTI BioPharma Reports Fourth Quarter and Full Year 2017 Financial Results-Management to Host Conference Call/ Webcast Today at 4:30 p.m. Eastern Time-SEATTLE,…
To view the full exhibit click here

About CTI BIOPHARMA CORP. (NASDAQ:CTIC)

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.